Dentroid Secures $32 Million for Needle-Free Dental Tech Partnership
Australian medtech firm Dentroid has raised $32 million at a $265 million valuation for its needle-free dental technology. The company also signed a global licensing deal with French manufacturer Septodont for its Nuralyte device, which uses light pulses for pain relief. This aims to reduce reliance on traditional dental injections.
Key points
- Canberra-based Dentroid raised $32 million in funding, valuing the company at $265 million.
- Dentroid's Nuralyte technology uses light pulses for dental analgesia, aiming to avoid needles.
- A global partnership and licensing agreement was signed with French dental product maker Septodont.
- The funding round saw participation from Septodont and local investors like Michael Gregg.
- Founded in 2017, Dentroid is led by CEO Omar Zuaiter and engineer Alaa Habeb.
Australian dental technology startup Dentroid announced it has successfully raised $32 million, achieving a company valuation of $265 million. This significant funding round was bolstered by a new strategic partnership with Septodont, a prominent French dental products manufacturer.
The deal includes a global licensing arrangement for Dentroid's flagship Nuralyte technology. This innovative system is designed to provide pain relief during dental procedures by utilizing pulses of light to induce analgesia in teeth and gums. The company's primary goal is to minimize or eliminate the need for traditional dental injections, thereby improving patient comfort.
Founded in Canberra in 2017 by CEO Omar Zuaiter and robotics engineer Alaa Habeb, Dentroid has dedicated its efforts over the past nine years to developing this needle-free approach. The recent funding saw contributions from Septodont itself, alongside investment from local backers including former WiseTech Global director Michael Gregg.
Sources
The WireByte editorial team synthesises technology news from multiple primary sources, verifies the facts, and links every source. Articles are produced with AI assistance and reviewed under our editorial policy.